Breaking News, Collaborations & Alliances

Keymed, Lepu Biopharma Enter Global License Agreement with AstraZeneca for CMG901

AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally.

Keymed Biosciences Inc., and Lepu Biopharma Co., Ltd., have entered into exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the terms of the agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. “We are pleased to have partnered with AstraZeneca, a global biopharmaceutical company with leadership in developing and commercializing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters